22 September 2023 - Eli Lilly announced today that NICE has recommended mirikizumab for the treatment of adults with moderately to severely active ulcerative colitis when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if:

• a tumour necrosis factor (TNF)-alpha inhibitor has not worked (that is the condition has not responded well enough or has lost response to treatment), or
• a (TNF)-alpha inhibitors cannot be tolerated or is not suitable

The NICE recommendation was based on results from the LUCENT program, which included two randomised, double-blind, placebo-controlled Phase 3 clinical trials, consisting of one 12-week induction study (LUCENT-1) and one 40-week maintenance study (LUCENT-2) for 52 weeks of continuous treatment.

Read Eli Lilly press release